Theravance Biopharma (TBPH) Enterprise Value (2014 - 2026)
Theravance Biopharma (TBPH) reported Enterprise Value of -$394.7 million for Q1 2026, down 201.61% year-over-year from $388.4 million in Q1 2025, and down 131.9% quarter-over-quarter from -$170.2 million in Q4 2025.
Theravance Biopharma (TBPH) Enterprise Value (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 13 years of Enterprise Value data on file, last reported at -$394.7 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$394.7 million, down 201.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$394.7 million (down 201.61% YoY), and the FY2025 annual result was -$170.2 million, down 92.63% from the prior year.
- Enterprise Value slipped to -$394.7 million in Q1 2026 per TBPH's latest filing, from -$170.2 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$88.4 million in Q4 2024 and troughed at -$486.8 million in Q3 2022.
- A 5-year average of -$195.7 million and a median of -$147.5 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value surged 72.47% in 2023, then sank 252.63% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$327.5 million in 2022, then surged by 68.72% to -$102.4 million in 2023, then advanced by 13.74% to -$88.4 million in 2024, then plunged by 92.63% to -$170.2 million in 2025, then slumped by 131.9% to -$394.7 million in 2026.
- Business Quant data shows TBPH's Enterprise Value at -$394.7 million in Q1 2026, -$170.2 million in Q4 2025, and -$177.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -584.73 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -394.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -394.67 Mn |
| Dec 31, 2025 | -170.19 Mn |
| Sep 30, 2025 | -177.16 Mn |
| Jun 30, 2025 | -338.80 Mn |
| Mar 31, 2025 | -130.86 Mn |
| Dec 31, 2024 | -88.35 Mn |
| Sep 30, 2024 | -91.36 Mn |
| Jun 30, 2024 | -96.08 Mn |
| Mar 31, 2024 | -99.98 Mn |
| Dec 31, 2023 | -102.43 Mn |
| Sep 30, 2023 | -134.00 Mn |
| Jun 30, 2023 | -167.45 Mn |
| Mar 31, 2023 | -241.26 Mn |
| Dec 31, 2022 | -327.48 Mn |
| Sep 30, 2022 | -486.83 Mn |
| Jun 30, 2022 | -132.85 Mn |
| Mar 31, 2022 | -147.52 Mn |
| Dec 31, 2021 | -173.47 Mn |
| Sep 30, 2021 | -216.21 Mn |
| Jun 30, 2021 | -264.95 Mn |